Advertisement

Topics

Kite Announces Publication of Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes

16:12 EDT 3 Aug 2017 | Speciality Pharma Journal

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD. The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive NHL subtypes including diffuse large …

Original Article: Kite Announces Publication of Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes

NEXT ARTICLE

More From BioPortfolio on "Kite Announces Publication of Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes"

Quick Search
Advertisement
 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...